You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 8,651,103


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,651,103
Title:Dry powder inhalation apparatus
Abstract: The invention relates to dry powder inhalation apparatus usually operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device (4) normally held adjacent a reservoir for receiving medicament in a cup or receptacle (15) and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device (4) is achieved by a yoke acting on an abutment (16) thereof. Spillage of medicament in the apparatus is avoided.
Inventor(s): Barney; Brian (Essex, GB), O'Leary; David (Essex, GB), Striebig; Rachel (London, GB)
Assignee: Norton Healthcare Ltd. (London, GB)
Application Number:10/574,386
Patent Claim Types:
see list of patent claims
Delivery; Device;
Patent landscape, scope, and claims:

United States Patent 8,651,103: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 8,651,103, titled "Dry powder inhalation apparatus," is a significant patent in the field of medical devices, particularly those related to respiratory care. This patent, assigned to Norton Healthcare Ltd, describes an innovative dry powder inhalation apparatus designed for controlled and smooth transfer of medicament. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Invention Overview

The patent, filed on October 2, 2003, and granted on February 18, 2014, addresses the need for an efficient and user-friendly dry powder inhalation apparatus. The invention is designed to improve the delivery of dry powder medicaments, ensuring a consistent and effective dose with each use[4].

Patent Scope

The scope of the patent is defined by its claims, which outline the specific features and functionalities of the invention. Here are some key aspects:

Independent Claims

The patent includes several independent claims that define the core elements of the invention. For example:

  • Claim 1 describes the dry powder inhalation apparatus with a mechanism for controlled transfer of the medicament, including a cam and a spring-loaded device[4].
  • Claim 10 outlines a method for operating the apparatus, emphasizing the smooth and bodily movement of the device to the discharge position[4].

Dependent Claims

Dependent claims further detail the specific components and their interactions. These include:

  • The use of a resilient member, such as a J-shaped plastic spring-like member, to flex out of the path of the device[4].
  • The incorporation of a pivotable stop and a button or plunger under spring pressure to facilitate the movement of the device[4].

Claim Analysis

The claims of the patent are crucial in defining the patent's scope and distinguishing it from prior art.

Claim Length and Count

Research suggests that the length and count of independent claims can be metrics for measuring patent scope. Narrower claims, as seen in this patent, are often associated with a higher probability of grant and a shorter examination process[3].

Claim Validity and Breadth

The patent's claims are designed to be specific enough to ensure the invention's uniqueness while being broad enough to cover various embodiments. The use of detailed descriptions and figures (e.g., FIG. 3, FIG. 4, FIG. 7) helps in clarifying the scope and preventing overly broad interpretations[4].

Patent Landscape

Understanding the patent landscape is essential for assessing the patent's position within the industry.

Prior Art and Citations

The patent cites several prior art references, indicating the evolution of dry powder inhalation technology. The Common Citation Document (CCD) application, which consolidates prior art citations from multiple offices, would be useful in identifying relevant prior art and ensuring the novelty of the invention[1].

Competing Patents

Other patents in the respiratory care sector, such as those related to inhalation devices, may intersect with the scope of this patent. For instance, patents listed in the Orange Book, which catalogues drug patents, could be relevant if they pertain to similar medical devices or delivery mechanisms[2].

Global Dossier and International Filings

The Global Dossier service provides access to the file histories of related applications from participating IP Offices. This can help in understanding the global patent family and any international filings related to this invention[1].

Regulatory and Competitive Impact

The listing of patents in regulatory databases can have significant competitive implications.

Orange Book Listings

Improper listings in the Orange Book, as highlighted by the FTC, can delay generic competition and increase healthcare costs. Ensuring accurate and relevant patent listings is crucial to avoid anticompetitive practices[2].

FDA Approval and Generic Competition

The automatic 30-month stay of FDA approval for generic drug applications due to listed patents can significantly impact the market. Proper patent listing and dispute resolution processes are essential to maintain fair competition[2].

Technical Harmonization and Global Integration

The patent landscape is influenced by international efforts to harmonize patent systems.

Common Citation Document (CCD)

The CCD application facilitates the integration of the global patent system by providing a single point of access to citation data from multiple offices. This helps in ensuring that the same invention is not patented multiple times, reducing redundancy and enhancing the efficiency of the patent system[1].

Examples and Illustrations

The patent includes detailed illustrations and descriptions of various embodiments, such as:

  • The use of an L-shaped abutment and a J-shaped plastic spring-like member to facilitate smooth device movement[4].
  • The incorporation of an electrical, electronic, or electro-mechanical actuator for automated operation[4].

Expert Insights and Statistics

Industry experts emphasize the importance of precise claim drafting to avoid overly broad patents, which can lead to increased licensing and litigation costs. For example, a study on patent scope metrics found that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Key Takeaways

  • Patent Scope and Claims: The patent's scope is defined by its specific claims, which outline the unique features of the dry powder inhalation apparatus.
  • Patent Landscape: Understanding prior art, competing patents, and global filings is crucial for assessing the patent's position.
  • Regulatory Impact: Accurate patent listings in regulatory databases are vital to avoid anticompetitive practices and ensure fair competition.
  • Technical Harmonization: International efforts like the CCD application enhance the efficiency and integration of the global patent system.

Frequently Asked Questions (FAQs)

What is the main invention described in US Patent 8,651,103?

The main invention is a dry powder inhalation apparatus designed for controlled and smooth transfer of medicament.

How does the patent's scope impact its validity?

The patent's scope, defined by its claims, must be specific enough to ensure uniqueness while avoiding overly broad interpretations that could lead to validity issues.

What is the significance of the Common Citation Document (CCD) in patent searching?

The CCD provides a single point of access to up-to-date citation data from multiple offices, facilitating the integration of the global patent system and ensuring that the same invention is not patented multiple times.

How can improper Orange Book listings affect generic competition?

Improper Orange Book listings can delay FDA approval of generic drug applications, leading to increased healthcare costs and reduced patient access to affordable alternatives.

What metrics can be used to measure patent scope?

Metrics such as independent claim length and independent claim count can be used to measure patent scope and assess the breadth and clarity of the claims.

Sources Cited

  1. USPTO, "Search for patents - USPTO," October 18, 2018.
  2. Federal Trade Commission, "Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book," November 7, 2023.
  3. SSRN, "Patent Claims and Patent Scope," September 29, 2016.
  4. Google Patents, "US8651103B2 - Dry powder inhalation apparatus," February 18, 2014.
  5. Unified Patents, "US-D783149-S1 - Respiratory Apparatus," October 2, 2003.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,651,103

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm PROAIR DIGIHALER albuterol sulfate POWDER, METERED;INHALATION 205636-002 Dec 21, 2018 DISCN Yes No 8,651,103 ⤷  Subscribe Y ⤷  Subscribe
Teva Branded Pharm PROAIR RESPICLICK albuterol sulfate POWDER, METERED;INHALATION 205636-001 Mar 31, 2015 RX Yes Yes 8,651,103 ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-004 Jul 12, 2019 DISCN Yes No 8,651,103*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-005 Jul 12, 2019 DISCN Yes No 8,651,103*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-006 Jul 12, 2019 DISCN Yes No 8,651,103*PED ⤷  Subscribe Y ⤷  Subscribe
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-001 Jan 27, 2017 RX Yes No 8,651,103*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,651,103

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0323085.1Oct 2, 2003
PCT Information
PCT FiledOctober 02, 2004PCT Application Number:PCT/US2004/032160
PCT Publication Date:April 21, 2005PCT Publication Number: WO2005/034833

International Family Members for US Patent 8,651,103

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 506094 ⤷  Subscribe
Australia 2004279379 ⤷  Subscribe
Canada 2540580 ⤷  Subscribe
Cyprus 1113531 ⤷  Subscribe
Germany 602004032361 ⤷  Subscribe
Denmark 1667627 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.